News

Roclatan achieved its primary efficacy endpoint of statistically significant superiority over each of its components on day 29. The Phase 2b 28-day clinical trial included 297 patients. The

The results from a randomized, non-inferiority, multicenter, comparative trial (N=758) establish that, despite a 29 % lower dose, Zubsolv provides equivalent efficacy compared to Suboxone film in patients

ALLOB is the first ever allogeneic differentiated osteoblastic cell therapy product developed for the treatment of orthopaedic conditions. Allogeneic cell therapy involves the harvesting of cells from a

Itonis has pre-paid necessary funds to Oasis to commence the inaugural production run. "The Company is excited that we have finally developed Emesyl to start production. We are

TrialOne is a browser-based bedside data collection technology designed specifically to address the needs of Phase I clinics. Subject recruitment, study data capture, sample tracking, reporting, data management

The research grant will be used to study the administration of a transmucosal Lorazepam Spray for the treatment of epileptic seizures in the outpatient settings. EastGate explores drug

Xiapex is the trade name for collagenase clostridium histolyticum (CCH) in the European Union (EU). Currently, Xiapex is approved to treat Dupuytren’s contracture in adult patients with a

The double-masked, randomized sham controlled trial is designed to evaluate the safety, tolerability and pharmacokinetics of QPI-1007 in these patients. QPI-1007 is a siRNA designed drug designed to

ADXS-cHER2 is being developed to target the Her2 receptor, which is overexpressed in certain solid-tumor cancers, including bone cancer (osteosarcoma), breast cancer, esophageal and gastric cancer. The company